Stark disparities in the outcome of myocardial infarction (MI) persist, with large unexplained variations affecting younger Black women. Mental stress–induced myocardial ischemia (MSIMI) is an ...

Abstract: Myocardial ischemia is one of the most prevalent cardiovascular diseases, underscoring the need for safer and effective therapeutic approaches. Peripheral nerve stimulation, particularly ...

DEAR DR. ROACH: Could you address intestinal angina? What are the symptoms, diagnostic tools and treatment? Is there any relation with it to gallbladder issues? I have experienced unexplained nausea ...

Abstract: This study developed and validated a non-contact clinical system for myocardial ischemia detection using a fiber optic sensor (FOS) placed under a mattress. A novel algorithm was introduced ...

The Global Myocardial Ischemia Market is estimated to be valued at USD 4.72 Bn in 2025 and is expected to reach USD 7.98 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2025 ...

A research team from the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has developed an innovative AI-based cardiovascular risk ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first month The Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, an ...

By accurately identifying individuals at higher risk of ischemic events in the critical early months after myocardial infarction (MI), this test empowers clinicians to make well-informed decisions ...

The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) remains uncertain. A comparison of immediate percutaneous coronary ...

Ischemic heart disease is the leading cause of death globally, causing approximately 9 million deaths annually. Currently, reperfusion therapy (such as thrombolysis or interventional procedures) is ...

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...